Agilent Technologies, a Santa Clara, California-based biotechnology research company, has selected New York City-based Turner Construction to build its $725 million manufacturing facility expansion in Frederick, Colorado, according to a press release.
Construction is scheduled to be complete in 2026, according to Turner.
The 200,000-square-foot project will increase Agilent’s capacity to meet demand for the company’s synthetic oligonucleotides, which help treat cancer, cardiovascular disease and other rare conditions, according to the release. Turner will build the facility in accordance with OSHA’s Process Safety Management standards, which cover the manufacturing of explosives and processes involving threshold quantities of flammable liquids, gasses and hazardous chemicals.
The synthetic oligonucleotides market is expected to grow in double digits annually over the next five years, totaling approximately $2.4 billion in 2027, according to an Agilent press release.
The announcement comes at a buoyant time for construction in the manufacturing sector. Dodge Construction Network pegged manufacturing starts to reach about $51.2 billion in 2023. Pharmaceutical labs associated with the manufacturing process, such as this Agilent facility, fall within that category.
Turner also recently won a $4.4 billion project for a Honda electric vehicle battery factory in Ohio, as well as a $1 billion EV battery recycling facility project in Kentucky, at the end of last year.
